Immunoglobulin G1 (IgG1), specifically the anti-human interleukin 5 (IL-5) monoclonal antibody SB-240563, is a recombinant therapeutic protein designed to target and neutralize IL-5, a cytokine involved in the regulation of eosinophils and implicated in various allergic and inflammatory conditions. This antibody is a dimeric structure formed by disulfide bonds between the heavy (g1-chain) and light (k-chain) chains, which is characteristic of IgG antibodies. IgG1 is known for its stability, long half-life in circulation, and ability to mediate immune responses through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation. The specificity of SB-240563 for IL-5 makes it a valuable tool in treating conditions like asthma and eosinophilic disorders by inhibiting the action of IL-5, thereby reducing eosinophil proliferation and survival. The CAS number 196078-29-2 uniquely identifies this specific monoclonal antibody, facilitating its recognition in scientific and regulatory contexts.

ImmunoglobulinG1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 g1-chain),disulfide with human-mouse monoclonal SB-240563 k-chain, dimer (9CI)

196078-29-2: Immunoglobulin G1 (IgG1), specifically the anti-human interleukin 5 (IL-5) monoclonal antibody SB-240563, is a recombinant therapeutic protein designed to target and neutralize IL-5, a cytokine involved in the regulation of eosinophils and implicated in various allergic and inflammatory conditions. This antibody is a dimeric structure formed by disulfide bonds between the heavy (g1-chain) and light (k-chain) chains, which is characteristic of IgG antibodies. IgG1 is known for its stability, long half-life in circulation, and ability to mediate immune responses through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation. The specificity of SB-240563 for IL-5 makes it a valuable tool in treating conditions like asthma and eosinophilic disorders by inhibiting the action of IL-5, thereby reducing eosinophil proliferation and survival. The CAS number 196078-29-2 uniquely identifies this specific monoclonal antibody, facilitating its recognition in scientific and regulatory contexts.

Mepolizumab (SB 240563) is a humanized monoclonal antibody neutralizing IL-5.

Mepolizumab

Monoclonal antibody for treatment of eosinophilic asthma

CAS 196078-29-2

ImmunoglobulinG1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 g1-chain),disulfide with human-mouse monoclonal SB-240563 k-chain, dimer (9CI)

Mepolizumab

Ref: TM-T9962

Mepolizumab

Ref: 3D-BM168494